Thromb Res

• 

  Publication Venue For

  • Comparison of Fibrin Monomers and D-dimers to predict thrombotic events in critically ill patients with COVID-19 pneumonia: A retrospective study..  205:8-10. 2021
  • A population-based analysis on the use of therapeutic plasma exchange and intravenous immunoglobulin in heparin-induced thrombocytopenia..  201:6-14. 2021
  • Catheter related thrombosis in hospitalized infants: A neural network approach to predict risk factors..  200:34-40. 2021
  • Thromboprophylaxis for orthopedic surgery; An updated meta-analysis..  199:43-53. 2021
  • COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy..  196:483-485. 2020
  • Meta-analysis fever in the wake of CARAVAGGIO..  196:141-142. 2020
  • Extracellular vesicles in atrial fibrillation and stroke..  193:180-189. 2020
  • Developing a model for predicting venous thromboembolism in obese pregnant women in a national study..  191:42-49. 2020
  • Anticoagulation and antiplatelet therapy in stable coronary artery disease: A multicenter survey..  180:25-27. 2019
  • The progression from coagulopathy to disseminated intravascular coagulation in representative underlying diseases..  179:11-14. 2019
  • International, multicenter evaluation of a new D-dimer assay for the exclusion of venous thromboembolism using standard and age-adjusted cut-offs..  166:63-70. 2018
  • Variants in chondroitin sulfate metabolism genes in thrombotic storm..  161:43-51. 2018
  • PF4-HIT antibody (KKO) complexes activate broad innate immune and inflammatory responses..  159:39-47. 2017
  • Management of hereditary antithrombin deficiency in pregnancy..  157:41-45. 2017
  • Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial..  156:184-190. 2017
  • Feasibility of the Von Willebrand disease PREVENT trial..  156:8-13. 2017
  • Generation and characterization of aptamers targeting factor XIa..  156:134-141. 2017
  • Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin..  146:113-118. 2016
  • Recognizing the risk of postpartum thrombosis among obese women and planning accordingly..  145:157-158. 2016
  • Low molecular weight heparin to prevent postpartum venous thromboembolism: A pilot study to assess the feasibility of a randomized, open-label trial..  142:17-20. 2016
  • Inter-observer reliability of the HERDOO2 clinical decision rule..  141:136-138. 2016
  • Systematic review of anticoagulant treatment of catheter-related thrombosis..  136:1103-1109. 2015
  • Characteristics and Risk Factors of Cancer Associated Venous Thromboembolism..  136:535-541. 2015
  • Whole blood gene expression profiles distinguish clinical phenotypes of venous thromboembolism..  135:659-665. 2015
  • Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U.S. cohort of commercial insurance enrollees..  135:50-57. 2015
  • Characterization of antithrombin levels in pregnancy..  134:648-651. 2014
  • A mouse bleeding model to study oral anticoagulants..  133 Suppl 1:S6-S8. 2014
  • Hemostasis: old system, new players, new directions..  133 Suppl 1:S1-S2. 2014
  • Thromboprophylaxis with fondaparinux in high-risk postoperative patients with renal insufficiency..  133:629-633. 2014
  • Differences in thrombotic risk factors in black and white women with adverse pregnancy outcome..  133:108-111. 2014
  • In vitro effects of recombinant activated factor VII on thrombin generation and coagulation following inhibition of platelet procoagulant activity by prasugrel..  132:106-111. 2013
  • Postpartum wound and bleeding complications in women who received peripartum anticoagulation..  132:e19-e23. 2013
  • Thrombosis in acute promyelocytic leukemia..  131:281-289. 2013
  • Characterization of the hypercoagulable state in patients with sickle cell disease..  130:e241-e245. 2012
  • The procoagulant properties of purified fibrinogen concentrate are enhanced by carbon monoxide releasing molecule-2..  129:793-796. 2012
  • Hemostatic properties of the FVIIa analog NN1731..  129 Suppl 2:S49-S50. 2012
  • Lack of association between serum paraoxonase-1 activity and residual platelet aggregation during dual anti-platelet therapy..  129:e36-e40. 2012
  • Obesity-related coagulation changes in pregnancy..  129:204-206. 2012
  • Time dependence of clopidogrel loading effect: platelet activation versus platelet aggregation..  129:1-2. 2012
  • Whole blood gene expression analyses in patients with single versus recurrent venous thromboembolism..  128:536-540. 2011
  • Homocysteinylated fibrinogen forms disulfide-linked complexes with albumin..  127:576-581. 2011
  • Elevated factor VIII enhances thrombin generation in the presence of factor VIII-deficiency, factor XI-deficiency or fondaparinux..  127:135-140. 2011
  • A time-tested ex vivo model of thrombosis: from pathophysiology to drug development and disease application..  126:363-364. 2010
  • Antiplatelet effects of aspirin with phytosterols: comparison with non-enteric coated aspirin alone..  126:384-385. 2010
  • The effect of aspirin on endothelial progenitor cell biology: preliminary investigation of novel properties..  126:e175-e179. 2010
  • Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy..  126:113-118. 2010
  • Anti-factor IXa Aptamer reduces propagation of thrombin generation in plasma anticoagulated with warfarin..  125:432-437. 2010
  • Platelet binding and activity of recombinant factor VIIa..  125 Suppl 1:S16-S18. 2010
  • Prevention and treatment of venous thromboembolism among patients with cancer: the American Society of Clinical Oncology Guidelines..  125 Suppl 2:S120-S127. 2010
  • Wound healing in hemophilia B mice and low tissue factor mice..  125 Suppl 1:S74-S77. 2010
  • Diagnosis and management of inherited von Willebrand disease in the next decade: panel discussion..  124 Suppl 1:S20-S21. 2009
  • Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease..  117:439-446. 2006
  • Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. 2017
  • Von Willebrand disease in women: awareness and diagnosis. 2009